Neoadjuvant Chemoradiotherapy and Consolidation Chemotherapy for Rectal Cancer: A Randomized Controlled Trial

Summary

The purpose of this protocol is to compare neoadjuvant chemoradiation plus consolidation chemotherapy before surgical resection with the standard neoadjuvant chemoradiation followed by surgical resection and adjuvant chemotherapy in patients with rectal cancer.

Eligibility

Inclusion Criteria:

* Histologically confirmed rectal adenocarcinoma
* cT3, cT4, threatened CRM / MRF, EMVI (+), ≥N1
* Multidisciplinary tumor board decision for neoadjuvant treatment
* Tumor distance from the anal verge \<15 cm based on endoscopy or magnetic resonance imaging
* Patient 18 to 80 years old
* General health condition status WHO 0-1
* Absence of co-morbidities that may affect treatment
* Neutrophils \>1,500 / mm3, platelets \>100,000 / mm3, hemoglobin\> 10 g / dL, normal creatinine, and creatinine clearance\> 50 mL / min
* Signed informed consent of the patient

Exclusion Criteria:

* Distant metastases
* Non-resectable cancer
* Contraindications for the administration of chemotherapy
* Previous pelvic radiotherapy or chemotherapy
* History of inflammatory bowel disorders
* History of angina, acute myocardial infarction or heart failure
* Active sepsis or systemic infection
* Untreated physical and mental disability
* Synchronous malignancy
* Pregnancy or breast-feeding
* Lack of compliance with the protocol process
* Non-granting of signed informed consent

Conditions2

Interventions2

Related trials

• Adjuvant Chemoradiotherapy Versus Chemotherapy for Pancreatic Cancer (ADJUPANC) — Changhai Hospital
• Adjuvant Chemotherapy in Clinical Local Advanced CRC Following Preoperational Therapies and pT0-3N0M0 Diagnosis — Sixth Affiliated Hospital, Sun Yat-sen University
• Adjuvant PD-1 Blockade for High-risk Stage-II DMMR/MSI-H Colorectal Cancer — Sun Yat-sen University
• Circulating and Urine Tumor DNA Dynamics Predict Minimal Residual Disease and Recurrence Risk in Locally Advanced Upper Tract Urothelial Carcinoma — RenJi Hospital
• Clinical Efficacy of Adjuvant Chemotherapy in Patients With Locally Advanced Cervical Cancer Who Did Not Meet the NCCN Guidelines for Adjuvant Treatment After NACT Combined With Surgery — Huazhong University of Science and Technology
• Neoadjuvant FOLFOXIRI Versus Immediate Surgery for Stage II and III Colon Cancers — Sun Yat-sen University
• Neoadjuvant SBRT Followed by Nab-Paclitaxel Combined With Toripalimab in HR+/HER2- Breast Cancer — Xijing Hospital
• OPTImaL:Optimisation of Treatment for Patients With Low Stage Triple-negative Breast Cancer With High Stromal Tumor-infiltrating Lymphocytes — The Netherlands Cancer Institute

Browse More Trials